Recombinant IL17A (Secukinumab Biosimilar) antibody

Catalog No. ABIN7795097

This Humanized Monoclonal antibody specifically detects IL17A (Secukinumab Biosimilar) in FACS and in vivo. It exhibits reactivity toward Human.

Quick Overview for Recombinant IL17A (Secukinumab Biosimilar) antibody (ABIN7795097)

Target: IL17A (Secukinumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Humanized

Clonality: Monoclonal

Conjugate: This IL17A (Secukinumab Biosimilar) antibody is un-conjugated

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Grade: Research Grade

Product Details anti-IL17A (Secukinumab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Secukinumab Biosimilar, Human IL17A Monoclonal Antibody

Characteristics: What is secukinumab biosimilar research grade? Research grade secukinumab biosimilar uses the same protein sequences as the therapeutic antibody secukinumab. Secukinumab, the humanized anti-IL17A monoclonal antibody, inhibits interleukin 17A, which is a member of the cytokine family, and produced mainly by inflammatory T helper 17 cells. IL17A is upregulated in serum of people with psoriasis and in the synovial fluid of people with psoriatic arthritis, and promotes inflammation when it binds to the interleukin-17 receptor which is expressed in various types of cells, including keratinocytes in skin.

Purification: Protein A or G affinity column

Purity: >95 % by reducing SDS-PAGE

Endotoxin Level: < 1 EU per 1 mg of the protein by the LAL method

Immunogen: Human IL17A

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: > 3 mg/mL

Storage: 4 °C,-20 °C

Storage Comment: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Target Details for IL17A (Secukinumab Biosimilar)

Target: IL17A (Secukinumab Biosimilar)

Alternative Name: Secukinumab Biosimilar

Target Type: Biosimilar